論文種別	原著論文
言語種別	英語
査読の有無	査読あり
表題	The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
掲載誌名	正式名：Clinical & experimental metastasis 略　 称：Clin Exp Metastasis ISSNコード：15737276/02620898
掲載区分	国外
巻・号・頁	36(364),pp.343-350
著者・共著者	Nakamura Tomoki, Tsukushi Satoshi, Asanuma Kunihiro, Katagiri Hirohisa, Ikuta Kunihiro, Nagano Akihito, Kozawa Eiji, Yamada Satoshi, Shido Yoji, Yamada Kenji, Kawanami Katsuhisa, Ishimura Daisuke, Sudo Akihiro, Nishida Yoshihiro
発行年月	2019/06
概要	The efficacy and safety of eribulin in Japanese patients with advanced soft-tissue sarcomas (STS) have not been evaluated in a large-scale cohort study. Thus, we aimed to investigate the clinical outcome of 82 Japanese patients with STS receiving eribulin across multiple study centers retrospectively. Of 82 STS patients receiving eribulin treatment, 13 were treated for locally unresectable tumor, 46 for metastasis, and 23 for both. The primary endpoint of this study was to evaluate the efficacy of eribulin against STS. The median age was 60 years. Thirty-seven were diagnosed with L-sarcoma (leiomyosarcoma or liposarcoma) and 45 had non-L-sarcoma. The median progression-free survival (PFS) for all patients was 2.7 months, with 3.4 months in those with L-sarcoma and 2.2 months in those with non-L-sarcoma. Patients with L-sarcoma showed a better PFS than those with non-L-sarcoma. Overall, the median survival time was 11.1 months, and 12.3 months and 7.9 months in patients with L-sarcoma and non-L-sarcoma, respectively; however, there was no significant differences between the groups. The prognostic significance of PS = 0 and both existence of local and metastatic STS was evaluated by multivariate analysis. We also evaluated the overall survival (OS) in patients with undifferentiated pleomorphic sarcoma (UPS) and other non-L-sarcomas. Patients with UPS had better OS than those with the other non-L-sarcomas. In conclusion, there was a significant difference in PFS between patients with L-sarcoma and non-L-sarcoma following treatment with eribulin. The anti-tumor potential of eribulin was evident in patients with UPS.
DOI	10.1007/s10585-019-09980-3
PMID	31209624